Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $1.2752W HIGH $3.56
Volume
171.70 K
Value Traded
400.46 K
Short % Float
4.87%
Days to Cover
4.4
+2.37%Week
-16.02%1 Month
+10.9%3 Month
-7.98%6 Month
-86.89%5 Year
-86.89%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
74.99 M
EPS (TTM)
-1.73
P/E Ratio
-
Ent. Value
-14.97 M
Total Shares
42.83 M
Float Shares
33.22 M
Insiders
22.47%
Institutions
45.37%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
ACRV Catalyst Timeline
Dated clinical, regulatory and corporate events for Acrivon Therapeutics, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Acrivon Therapeutics, Inc.
134Total events
8Upcoming
25Tier-1 (high impact)
2022 to 2027Coverage
Upcoming catalysts 2
Event history 50
▲Preclinical PoCACR-7280Preclinical
ACR-7280 showed complete tumor regression in aggressive AML xenograft models
acute myeloid leukemia (AML)source ↗
▲Development Candidate NominationACR-7280Preclinical
ACR-7280 advanced as next development candidate, an oral CDK11 inhibitor
acute myeloid leukemia (AML)source ↗
▲Trial InitiationACR-2316Trial
ACR-2316 advances into randomized dose expansion in ongoing Phase 1/2 study
solid tumorssource ↗
▲Dose Finding UpdateACR-2316Trial
Dose levels selected for randomized dose expansion: 120 mg and 160 mg QD
solid tumorssource ↗
▲Safety Data UpdateACR-2316Clinical Data
Favorable, differentiated safety profile reported for ACR-2316
solid tumorssource ↗
◆Trial InitiationACR-368FiledTrial
Achieve readiness for Phase 3 confirmatory trial for ACR-368 in combination with PD-1 therapy
serous endometrial cancersource ↗
◆Topline ReadoutACR-368FiledClinical Data
Additional update on Arm 1 and initial clinical data from Arm 3 expected mid-2026
endometrial cancersource ↗
◆Topline ReadoutACR-368FiledClinical Data
Initial clinical data for ACR-368 + ULDG sensitization in OncoSignature-negative endometrial cancer
endometrial cancersource ↗
◆Trial InitiationACR-368FiledTrial
Achieve readiness for Phase 3 confirmatory trial for ACR-368 in combination with PD-1 therapy
endometrial cancersource ↗
▲Enrollment CompleteACR-368FiledTrial
Completed exploratory Arm 2 (BM- EC subjects with 3 prior LoT)
endometrial cancersource ↗
▲Topline ReadoutACR-368FiledClinical Data
Topline data presented at KOL panel on February 27, 2026
endometrial cancersource ↗
●Oral PresentationACR-368FiledPresentation
KOL panel discussion presenting ACR-368 clinical data
endometrial cancersource ↗
▲Topline ReadoutACR-368FiledClinical Data
ACR-368 Phase 2b clinical data presented (ORR 39% in BM+, 26% in BM- with ULDG, 44% in BM+ single agent)
endometrial cancersource ↗
◆Topline ReadoutACR-2316Clinical Data
ACR-2316 Phase 1 initial clinical data presented
AP3-identified tumor typessource ↗
▲Development Candidate NominationPreclinical
Nomination of cell cycle program development candidate
cell cycle programsource ↗
●Development Candidate NominationACR-6840Preclinical
ACR-6840 nominated as next preclinical development candidate
▲Oral PresentationACR-368FiledPresentation
Late-breaking oral presentation at ESGO 2026 highlighting ACR-368 data in serous EC
serous endometrial cancersource ↗
▲Development Candidate NominationACR-6840Preclinical
Nominated ACR-6840 as development candidate
◆Other Regulator MilestoneACR-368FiledEx-US Regulatory
Achieve CTA approval in EU for Arm 3
serous endometrial cancersource ↗
●Enrollment UpdateACR-368FiledTrial
EU CTA submitted for Arm 3; initial EU enrollment expected Q1 2026
serous endometrial cancersource ↗
●Quarterly UpdateCorporate
Preliminary unaudited cash position of ~$119M as of Dec 31, 2025; expected to fund into Q2 2027
▲First Patient DosedACR-2316Trial
Initial data from Phase 1 dose escalation (N=33) for ACR-2316
solid tumorssource ↗
▲Topline ReadoutACR-368FiledClinical Data
Updated interim analysis of ACR-368 Phase 2b monotherapy in OncoSignature-positive endometrial cancer shows 39% ORR
endometrial cancersource ↗
▲Enrollment CompleteACR-2316Trial
Enrollment in first three dose-escalation cohorts completed for ACR-2316 Phase 1 trial
AP3-prioritized solid tumor typessource ↗
●Oral PresentationPresentation
Presentations at AACR-NCI-EORTC International Conference on AP3 platform and ACR-2316 preclinical data
●NDA SubmissionACR-368FiledRegulatory Filing
Submitted Phase 3 confirmatory protocol to FDA for ACR-368 plus anti-PD-1 in frontline EC
endometrial cancersource ↗
▲Trial InitiationACR-368FiledTrial
Initiated Arm 3 (ACR-368 + ULDG) in all-comer serous EC
serous endometrial cancersource ↗
▲Enrollment UpdateACR-368FiledTrial
Initiated third arm of Phase 2b trial with ACR-368 + ultra low-dose gemcitabine in all-comer 2nd line endometrial cancer
endometrial cancersource ↗
▲Enrollment UpdateACR-2316Trial
Continued enrollment in Phase 1 dose-escalation; three dose levels cleared with no DLTs
solid tumorssource ↗
◆Timing GuidanceACR-368FiledPresentation
Provide update on registrational-intent trial and confirmatory trial design in H2 2025
endometrial cancersource ↗
◆Topline ReadoutACR-2316Clinical Data
Report initial clinical data from Phase 1 study of ACR-2316 in H2 2025
solid tumorssource ↗
●Type B MeetingACR-368FiledFDA Meeting
Type B meeting with FDA for ACR-368 Phase 3 confirmatory study
endometrial cancersource ↗
▲First Patient DosedACR-2316Trial
Three dose escalation cohorts completed in ACR-2316 Phase 1 trial
solid tumorssource ↗
◆Topline ReadoutACR-2316Clinical Data
Initial clinical data from monotherapy Phase 1 dose optimization trial expected
selected solid tumorssource ↗
◆Topline ReadoutACR-368FiledClinical Data
Initial clinical data for ACR-368 monotherapy in OncoSignature-positive endometrial cancer
endometrial cancersource ↗
●Oral PresentationACR-2316Presentation
AACR presentation of ACR-2316 preclinical data
solid tumorssource ↗
◆Dose Finding UpdateACR-2316Trial
Safety observation period for dose level 3 anticipated to be completed by April 1
advanced solid tumorssource ↗
▲Enrollment CompleteACR-2316Trial
Enrollment completed in first three dose-escalation cohorts of ACR-2316 Phase 1 trial
advanced solid tumorssource ↗
Past FDA Catalysts and PDUFA Decisions
How ACRV actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2025-06-30 | ACR-368 | Phase 2 data readout | Phase 2 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
2
Drugs Scored
rNPV / MCap
Top Drug
Top 52%
Micro Cap(rank 342 of 657)
Percentile Rank
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ACR-2316 Small moleculeNCT06667141 | Specific Advanced Solid Tumors | Phase 1 | RECRUITING | 100 | Dec 12, 2027 | ||||||
| ACR-368 Small moleculeNCT05548296 | Endometrial Adenocarcinoma | Phase 2 | RECRUITING | 350 | Nov 30, 2027 |
Clinical Trial Results
Readouts, endpoints and source filings for every ACRV program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| ACR-368 BreakthroughFast Track | serous endometrial cancer | Phase 2b | 2026-05-13 | cORR of 52% (N = 23) in serous EC subjects versus an ORR of 22% (N = 37) in non-serous EC subjectsRead More | Acrivon Reports First Quarter 2026 Financial Results and Highlights Progress Towards Key 2026 Clinical Catalysts The registrational intent ACR-368 Phase 2b study is advancing with a prespecified simultaneous interim analRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Miller MaryOfficer (Chief Legal Officer) | Sell | -294 81,715 held | $1.99 | 10/05/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in ACRV
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 0.2 % (100 %) | 21.77 M | 12.23 M | 46.63% ( 3.89 M) |
ACRV Institutional Ownership Trends
ACRV Short Interest
Shares sold short, counted twice a month.
4.87%
Short % of Float
of tradable shares sold short
1.6M
Shares Sold Short
+34.4% vs prior count
4.4 Moderate
Days to Cover
trading days of normal volume to buy every short share back
367.5K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How ACRV ranks across every disease it competes in
Competitive Position is a premium feature
See how ACRV ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialACRV News
ACRV▲ +6.2%on this news
Acrivon Advances ACR-7280, an Optimized, AP3-Enabled, Potential First-in-Class, Oral CDK11 Inhibitor Toward IND Filing in First Half of 2027
Acrivon Therapeutics is advancing ACR-7280, a potential first-in-class oral CDK11 inhibitor, toward an IND filing expected in the first half of 2027. The drug has shown complete tumor regression in aggressive AML xenograft models and demonstrates strong synergy with other treatments. The company is leveraging its proprietary AP3 platform for rational drug design and predictive clinical development.
Read more →ACRVAcrivon Therapeutics to Present at the 2026 Cantor Global Healthcare Conference
Acrivon Therapeutics will present at the 2026 Cantor Global Healthcare Conference, with CEO Peter Blume-Jensen participating in a fireside chat. The company is advancing its lead program ACR-368 in a Phase 2 trial for endometrial cancer and has received Fast Track designation from the FDA. Additionally, Acrivon is developing ACR-2316, a selective WEE1/PKMYT1 inhibitor, which is showing promising clinical activity.
Read more →ACRVAcrivon Therapeutics Appoints Michaela Levin, Ph.D., as Chief Business Officer
Acrivon Therapeutics has appointed Michaela Levin, Ph.D., as Chief Business Officer. Levin is an experienced biotechnology executive with a strong background in business development, strategic transactions, and corporate strategy. Her appointment is anticipated to bolster Acrivon's strategic initiatives and growth in the industry.
Read more →ACRV▲ +7.6%on this news· ran to +19% by day 3
Acrivon Reports Second Quarter 2026 Financial Results and Highlights Upcoming 2026 Clinical Data Catalysts
Acrivon has reported its financial results for Q2 2026, highlighting the progress of its clinical trials. The ACR-368 Phase 2b interim analysis is scheduled for the second half of 2026, while the ACR-2316 trial is advancing into a randomized dose expansion phase. The promising safety data from ACR-2316 supports its continued development.
Read more →ACRV▲ +5.1%on this news
Acrivon Advances ACR-2316, a Potential First-in-Class WEE1/PKMYT1 Inhibitor, into Randomized Dose Expansion in its Ongoing Phase 1/2 Study
Acrivon has advanced its investigational drug ACR-2316, a potential first-in-class WEE1/PKMYT1 inhibitor, into the randomized dose expansion phase of its ongoing Phase 1/2 study. The drug has demonstrated a favorable safety profile and durable clinical activity, particularly in heavily pretreated lung cancer patients. The selected oral regimen includes a weekly dosing schedule.
Read more →ACRVAcrivon to Highlight the Power of its AP3 Platform for Streamlined, Pathway-Based Drug Discovery and Development with Oral and Poster Presentations at AACR D3 Conference
Acrivon is set to present its AP3 platform at the AACR D3 Conference, showcasing mechanistic data on ACR-2316, a promising WEE1/PKMYT1 inhibitor. The drug has demonstrated early clinical responses, including partial responses in patients. The presentations aim to emphasize the platform's capabilities in facilitating pathway-based drug discovery and development.
Read more →ACRVAcrivon Therapeutics to Present at TD Cowen’s 7th Annual Oncology Innovation Summit
Acrivon Therapeutics will present at TD Cowen's 7th Annual Oncology Innovation Summit on May 26, 2026. The company's CEO, Peter Blume-Jensen, will participate in a virtual fireside chat. Acrivon is focused on developing precision medicines using its proprietary AP3 platform, with ongoing studies for ACR-368 and ACR-2316 showing promising results.
Read more →ACRV▼ -6.8%on this newsshared move
Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Acrivon Therapeutics announced an equity award grant under its 2023 Inducement Plan to an employee, consisting of stock options for 111,150 shares. This grant is part of the company's strategy to attract and retain talent. Acrivon is also progressing its lead program, ACR-368, in a Phase 2 trial for endometrial cancer, which has received FDA Fast Track designation.
Read more →ACRVAcrivon Reports First Quarter 2026 Financial Results and Highlights Progress Towards Key 2026 Clinical Catalysts
Acrivon Therapeutics reported its financial results for Q1 2026, highlighting the progress of its key clinical programs, ACR-368 and ACR-2316. The ACR-368 Phase 2b study for serous endometrial cancer is advancing with a simultaneous interim analysis planned for late 2026. Meanwhile, ACR-2316 exhibited initial favorable safety and activity data in challenging tumor types like small cell lung cancer. The company reports a cash position of $97.7 million, supporting operations into 2027.
Read more →ACRVAcrivon to Highlight Preclinical Data with Three Posters at AACR Demonstrating Strong ACR-368 and ACR-2316 Synergies with Immune Checkpoint Inhibitors and ADC Payloads, Revealing Broad Clinical Development Opportunities
Acrivon Therapeutics announced promising preclinical data at the AACR 2026 Annual Meeting, showcasing the strong synergies of its lead assets, ACR-368 and ACR-2316, with immune checkpoint inhibitors and Topo 1 inhibitors. The findings suggest significant opportunities for future clinical development in cancer treatment. ACR-368 is currently in a registrational Phase 2b study, while ACR-2316 is in Phase 1/2.
Read more →ACRVAcrivon Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
Acrivon Therapeutics reported its fourth quarter and full year 2025 financial results, highlighting promising data from its ACR-368 Phase 2b study which indicated a 52% confirmed overall response rate in serous endometrial cancer. The company has initiated an additional cohort in the study and expressed strong clinical momentum supported by positive key opinion leader commentary. Additionally, initial data from ACR-2316 has shown favorable tolerability and promising clinical activity in lung cancer. With a financial position allowing operations to continue into mid-2027, Acrivon appears well-positioned for future growth.
Read more →ACRV▼ -17.9%on this news
Forward-looking statements Certain information contained in this presentation and related webcast includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 regarding o
Acrivon Therapeutics presented forward-looking statements regarding ACR-368 during its recent KOL panel discussion. The presentation highlighted ACR-368's potential as a treatment for endometrial cancer and the use of a novel biomarker test designed to predict patient response. Despite the optimistic outlook, the implications of the findings remain uncertain due to potential risks and the inherent unpredictability associated with clinical trials.
Read more →ACRV▼ -34.6%on this news
ACR-368 AND ACR-2316 CLINICAL DATA AND AP3
Acrivon Therapeutics provided clinical updates on ACR-368 and ACR-2316 during their January 2026 conference call, showcasing both molecules' potential in treating various cancers. ACR-368, a selective CHK1/2 inhibitor, indicates favorable outcomes in endometrial cancer with a new trial underway, while ACR-2316 has shown encouraging initial data. The company emphasized the effectiveness of its AP3 platform for precision drug development, though market challenges remain. Additionally, the outcomes of these programs are uncertain until more data is available from ongoing clinical trials.
Read more →ACRV▼ -34.6%on this news
Acrivon Therapeutics Announces Positive ACR-368 Phase 2b Endometrial Cancer Clinical Data with EU Expansion to Accelerate Enrollment, Initial ACR-2316 Clinical Data, and ACR-6840, its Next AP3-Enabled Development Candidate, Targeting CDK11
Acrivon Therapeutics has reported positive data from its ongoing ACR-368 Phase 2b trial, showing an overall response rate of 39%, with significant results for patients with serous endometrial cancer. Additionally, the company has submitted a Phase 3 study protocol to the FDA for ACR-368 in combination with anti-PD-1 therapy. Preliminary findings from the Phase 1 study of ACR-2316 also indicate favorable tolerability and tumor shrinkage in some patients. The firm plans to expand its clinical trials into Europe, aiming for quicker patient enrollment.
Read more →ACRV▼ -9.2%on this news
Acrivon Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights
Acrivon Therapeutics reported its financial results for Q3 2025, highlighting the progression of its lead asset ACR-368 in a registrational-intent Phase 2b trial for endometrial cancer. The company is well-funded with $134.4 million in cash, which is expected to support its operations through mid-2027. Additionally, Acrivon is advancing ACR-2316, showing promising early clinical activity. However, the company's net loss indicates it is still navigating financial challenges as it advances its pipeline.
Read more →ACRVForward-looking statements Certain information contained in this presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 regarding our future results of
Acrivon Therapeutics presented a corporate overview emphasizing its commitment to precision medicine through its Predictive Precision Proteomics (AP3) platform. The company highlights ongoing clinical trials and the potential of its drug candidates, notably ACR-368. However, it also cautions stakeholders about the inherent risks and uncertainties associated with forward-looking statements, which may not always predict actual outcomes. The management urges caution against placing undue reliance on these statements as they navigate future developments.
Read more →ACRVAcrivon Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights
Acrivon Therapeutics reported its second quarter 2025 financial results, highlighting significant progress in clinical trials for its two lead assets, ACR-368 and ACR-2316. ACR-368 is in a registrational-intent Phase 2b trial for endometrial cancer, showing promising treatment responses. Meanwhile, ACR-2316 is advancing in Phase 1 trials with demonstrated initial activity and no observed dose-limiting toxicities. The company maintains a robust cash position of $147.6 million, which it anticipates will support operations into 2027.
Read more →ACRVAcrivon Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights
Acrivon Therapeutics has reported its first-quarter financial results for 2025, highlighting positive interim data from the ACR-368 Phase 2b trial in endometrial cancer patients. The data demonstrated a confirmed overall response rate of 35% and effective treatment responses in previously refractory patients. The company also observed tumor shrinkage in patients treated with ACR-2316 and announced the appointment of Mansoor Raza Mirza, M.D. as the new chief medical officer. With a strong cash position of $164.8 million, Acrivon is well-positioned to continue advancing its clinical pipeline.
Read more →ACRV▼ -7.9%on this news
Acrivon Therapeutics Appoints World-Renowned Oncology Key Opinion Leader and Clinical Investigator Mansoor Raza Mirza, M.D., as Chief Medical Officer
Acrivon Therapeutics has appointed Dr. Mansoor Raza Mirza as the new Chief Medical Officer, effective April 9, 2025. Dr. Mirza, a distinguished oncologist with extensive experience in gynecological oncology, will oversee clinical development including the Phase 2b ACR-368 trial for endometrial cancer and the Phase 1 ACR-2316 study. His appointment comes at a pivotal time for Acrivon, with promising clinical data for its drug candidates aiding in potential regulatory submissions.
Read more →About Acrivon Therapeutics, Inc.
Headquarters480 ARSENAL WAY, SUITE 100, WATERTOWN, MA, 02472
Founded2018
BIOPHARMAWATCH ELITE PLUS
Trade the next ACRV catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime